Amgen
Mirati heads for FDA verdict on KRAS drug with new data
Phil Taylor
adagrasib, Amgen, asco, KRAS, Lumakras, Mirati, Non-small cell lung cancer
0 Comment
AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3
Phil Taylor
Amgen, KRAS, Lumakras, Mirati, Non-small cell lung cancer, Novartis, novel targeted cancer treatments, Oncology
0 Comment
NICE ends UK access disparity to osteoporosis drug Evenity
Phil Taylor
Amgen, Evenity, HEOR, NHS, osteoporosis, UCB
0 Comment
Amgen eyes pancreatic cancer use for its pathfinder KRAS drug
Phil Taylor
Amgen, KRAS, Lumakras, Mirati, pancreatic cancer
0 Comment
Amgen grabs EU approval for pathfinder KRAS drug Lumykras
Phil Taylor
Amgen, KRAS, Lumakras, Lumykras, Non-small cell lung cancer, Oncology, targeted oncology
0 Comment
Amgen pledges $1.9bn to alliance with AI specialist Generate
Phil Taylor
Amgen, artificial intelligence, drug discovery, Generate Biomedicines, protein
0 Comment
News/ News/ Sales and Marketing
Novartis bags elusive US approval for cholesterol drug inclisiran
Phil Taylor
Amgen, cholesterol, inclisiran, Leqvio, Novartis, PCSK9, Praluent, Regeneron, regulatory approval, Repatha, Sanofi
0 Comment
News/ News/ Sales and Marketing
Amgen builds Otezla’s psoriasis label as rival BMS looms large
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, Otezla, psoriasis, sales & marketing
0 Comment